Fibrates in combination with statins in the management of dyslipidemia

Area of Science:

• Cardiology
• Pharmacology
• Metabolic Disorders

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary hypercholesterolemia target.
• High triglycerides (TG) and low high-density lipoprotein cholesterol (HDL-C) are crucial therapeutic targets, especially in hypertensive individuals.
• Lipid management is integral to cardiovascular disease prevention.

Purpose of the Study:

• To evaluate the role of fibrates in managing dyslipidemia, particularly in combination with statins.
• To compare the safety and efficacy of fenofibrate versus gemfibrozil when used concurrently with statins.
• To assess the risk of myopathy and rhabdomyolysis associated with combined statin-fibrate therapy.

Main Methods:

• Review of existing literature on fibrate efficacy and safety.
• Analysis of studies comparing fenofibrate and gemfibrozil in combination with statins.
• Examination of the pharmacokinetic interactions between fibrates and statins, focusing on glucuronidation pathways.

Main Results:

• Fibrates are effective in reducing TG and increasing HDL-C, leading to reduced cardiovascular events.
• Combination therapy with statins and fibrates can be beneficial for patients not at lipid goals.
• Gemfibrozil, unlike fenofibrate, interferes with statin glucuronidation, increasing the risk of statin-associated myopathy.

Conclusions:

• Combination therapy with statins and fibrates offers a valuable strategy for atherogenic lipid profiles.
• Fenofibrate presents a more favorable safety profile than gemfibrozil when co-administered with statins, due to a lower risk of myopathy.
• Optimizing lipid management in hypertensive patients requires addressing TG and HDL-C alongside LDL-C.